pyrroles has been researched along with Infections in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, S; Lee, E; Lee, KW | 1 |
| Abrahamowicz, M; Bernatsky, S; Curtis, JR; Guerra, SF; Machado, MAÁ; Moura, CS | 1 |
| Biswas, P; Choy, E; Clark, JD; Hazra, A; Hodge, J; Krishnaswami, S; Lazariciu, I; Lee, EB; Mojcik, C; Strengholt, S; Valdez, H; van Vollenhoven, R; Wang, L | 1 |
| Click, B; Regueiro, M | 1 |
| Atzeni, F; Bechman, K; Cope, AP; Galli, M; Galloway, JB; Norton, S; Subesinghe, S; Winthrop, KL | 1 |
| Zand, MS | 1 |
| Fukuyo, S; Hirata, S; Kubo, S; Maeshima, K; Saito, K; Sonomoto, K; Suzuki, K; Tanaka, Y; Yamaoka, K | 1 |
| Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Winthrop, KL | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Rouleau, J | 1 |
| Chisholm, DR; Leitner, F; Misiek, M; Price, KE | 1 |
6 review(s) available for pyrroles and Infections
| Article | Year |
|---|---|
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Humans; Immune System Diseases; Immunity, Innate; Indoles; Infections; Isoquinolines; Lysosomes; Maprotiline; Metformin; Neoplasms; Phenols; Pyrroles; Resveratrol; Sirolimus; Spermidine; Stilbenes; Tetrahydroisoquinolines; Trehalose | 2017 |
Managing Risks with Biologics.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Demyelinating Diseases; Deprescriptions; Drug Substitution; Gastrointestinal Agents; Humans; Infections; Inflammatory Bowel Diseases; Lymphoma; Melanoma; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk; Risk Assessment; Skin Neoplasms; Tumor Necrosis Factor-alpha; Ustekinumab | 2019 |
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Infections; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Tofacitinab in renal transplantation.
Topics: Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors | 2013 |
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Infections; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Prevalence; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2014 |
The emerging safety profile of JAK inhibitors in rheumatic disease.
Topics: Azetidines; Humans; Infections; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Signal Transduction; Sulfonamides | 2017 |
3 trial(s) available for pyrroles and Infections
| Article | Year |
|---|---|
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Topics: Adult; Aged; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Proliferation; Double-Blind Method; Female; Humans; In Vitro Techniques; Infections; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
6 other study(ies) available for pyrroles and Infections
| Article | Year |
|---|---|
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2018 |
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; B-Lymphocytes; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Incidence; Infections; Janus Kinase Inhibitors; Killer Cells, Natural; Lymphocyte Count; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors | 2019 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Microbiological and pharmacological evaluation of BL-C 43, a new semisynthetic derivative of coumermycin A1.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Coumarins; Infections; Mice; Microbial Sensitivity Tests; Pyrroles | 1969 |